Transapical transcatheter aortic valve implantation in patients with aortic diseases

Author:

Useini Dritan1ORCID,Beluli Blerta2,Christ Hildegard3,Schlömicher Markus1,Ewais Elias1,Patsalis Polykarpos4,Haldenwang Peter1,Naraghi Hamid1,Moustafine Vadim1,Bechtel Matthias1,Strauch Justus1

Affiliation:

1. Department of Cardiothoracic Surgery, Ruhr-University Hospital Bergmannsheil, Bochum, Germany

2. Department of Internal Medicine, St. Anna Hospital, Herne, Germany

3. Department of Medical Statistics, Institute of Medical Statistics and Computational Biology (IMSB), University Hospital of Cologne, Cologne, Germany

4. Department of Cardiology and Angiology, Ruhr-University Hospital Bergmannsheil, Bochum, Germany

Abstract

Abstract OBJECTIVES Patients scheduled for transcatheter aortic valve implantation (TAVI) treatment frequently present with concomitant aortic diseases, in which case they are usually considered to be at high interventional risk and, in particular, unable to undergo the transfemoral TAVI approach. Since the establishment of the ‘transfemoral first’ strategy for TAVI, there has been an evidence gap with regard to the outcomes of such patients. We aimed to evaluate the mid-term outcomes after transapical TAVI in patients with diverse aortic diseases. METHODS Fifty-five consecutive elderly patients (78.4 years; standard deviation: 8.6 years) at intermediate surgical risk with severe aortic stenosis and aortic diseases (porcelain aorta 36%, ascending aneurysm 15%, descending aneurysm 26%, type-B dissection 4%, aortic thrombus 7%, Leriche syndrome 4%, aortic kinking 11%, aortic ulcer 2%, previous aortic operation 20%, aortic elongation/tortuosity 4%) underwent transapical TAVI treatment between January 2011 and November 2019 at our institution. We used the second-and third-generation self- and balloon-expanding valves. The follow-up time was 92.6 patient-years. RESULTS The Society of Thoracic Surgery-Predicted Risk of Mortality score was 7% (standard deviation: 4%). The 30-day mortality and all-stroke rates were 6% and 4%, respectively. The median survival time was 24.9 months (95% confidence interval 17.6–32.3). The median time of freedom from a composite of death and cardio-cerebral adverse events was 24.3 months (95% confidence interval 11.9–36.8). The rate of moderate/severe paravalvular leakage was 2%. The pacemaker rate was 10%. No early or late aortic syndrome occurred. CONCLUSIONS Transapical TAVI is a safe method and shows very promising early and mid-term outcomes, without early/late aortic syndrome, in patients with aortic diseases for whom transfemoral TAVI as the first-line transcatheter method might be contraindicated or not feasible.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,General Medicine,Surgery

Reference25 articles.

1. German Transcatheter Aortic Valve Interventions Registry Investigators. Transcatheter aortic valve implantation in patients with "porcelain" aorta (from a Multicenter Real World Registry);Zahn;Am J Cardiol,2013

2. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery;Leon;N Engl J Med,2010

3. Mid-term outcomes after transapical and transfemoral transcatheter aortic valve implantation for aortic stenosis and porcelain aorta with a systematic review of transfemoral versus transapical approach;Useini;Thorac Cardiovasc Surg,2019

4. Transcatheter aortic valve implantation in patients with ascending aortic dilatation: safety of the procedure and mid-term follow-up;Rylski;Eur J Cardiothorac Surg,2014

5. Impact of aortic aneurysms in trans-catheter aortic valve replacement: a single center experience;Kobayashi;Indian Heart J,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3